Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of plonmarlimab in rheumatic disease-associated hemophagocytic lymphohistiocytosis/macrophage activation syndrome
CTR20230579Phase 2Completed
- Sponsor
- Tianjing Biopharma
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of plonmarlimab in haemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), sponsored by Tianjing Biopharma. Started Apr 2023; status: completed.
02
Drugs
plonmarlimab
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)macrophage activation syndrome (MAS)
Beyond the preview
Go deeper on CTR20230579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230579.